HC Wainwright restated their buy rating on shares of Grace Therapeutics (NASDAQ:GRCE – Free Report) in a report issued on Tuesday,Benzinga reports. HC Wainwright currently has a $12.00 price objective on the stock.
Grace Therapeutics Trading Down 0.9 %
NASDAQ:GRCE opened at $3.42 on Tuesday. Grace Therapeutics has a 52 week low of $2.13 and a 52 week high of $4.97. The company has a market capitalization of $34.68 million, a price-to-earnings ratio of -3.39 and a beta of 1.36. The business’s 50-day simple moving average is $3.68.
Grace Therapeutics (NASDAQ:GRCE – Get Free Report) last released its earnings results on Thursday, February 13th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.01. As a group, analysts anticipate that Grace Therapeutics will post -0.98 EPS for the current fiscal year.
About Grace Therapeutics
Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.
Featured Articles
- Five stocks we like better than Grace Therapeutics
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- Expert Stock Trading Psychology Tips
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for Grace Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grace Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
